Deferasirox

{
  "id": "MLC-T-ONC-002330",
  "term": "Deferasirox",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used to treat too much iron in the blood caused by blood transfusions. It is being studied in the treatment of myelodysplastic syndromes (a group of diseases in which the bone marrow does not make enough healthy blood cells) and other conditions. Deferasirox binds to extra iron in the blood. The drug and the iron are passed from the body in urine. It is a type of chelating agent. Also called Exjade.",
    "A synthetic, orally bioavailable, achiral, tridentate triazole derived from salicylic acid with iron-chelating activity. Deferasirox chelates iron at a 2:1 (ligand:iron) ratio. Because of its oral availablity,and long plasma half-life, this agent may be superior to desferrioxamine (desferal, DFO), which is orally inactive and has a short plasma half-life."
  ],
  "synonyms": [
    "Exjade"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/deferasirox/"
}